Transport
Spartanburg Medical Center
Spartanburg Medical Center was paid $187.76M by Medicaid between Jan 2018 and Dec 2024, across 632 billing codes. Its largest line is 80053, Comprehensive metabolic panel — 8.8% of everything it billed.
33Billing provider infoSPARTANBURG MEDICAL CENTER
SPARTANBURG, SC 29303
SPARTANBURG, SC 29303
33aNPI1609807122assigned 07/05/2006
33bProvider typeAmbulance
28Total paid$187.76M
24GClaims3,806,991
24DCodes billed632
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in South Carolina
Rank by total paid#1 of 51
Median peer was paid$630K
This provider vs. median298×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MEINKE, KENNETH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 419,238 | $19.78M | |
| 2019 | 558,324 | $28.10M | |
| 2020 | 501,532 | $26.31M | |
| 2021 | 575,345 | $30.80M | |
| 2022 | 649,193 | $31.71M | |
| 2023 | 610,639 | $29.16M | |
| 2024incomplete | 492,720 | $21.90M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 8.8% | 164,067 | 134,903 | $16.62M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5.2% | 28,982 | 26,175 | $9.77M |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 4.8% | 18,714 | 13,212 | $9.02M |
| J7030 | Infusion, normal saline solution , 1000 cc | 4.4% | 46,507 | 34,876 | $8.27M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.2% | 110,819 | 90,695 | $7.83M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.9% | 128,416 | 112,546 | $7.33M |
| J7050 | Infusion, normal saline solution, 250 cc | 3.3% | 12,258 | 9,051 | $6.12M |
| 36415 | Collection of venous blood by venipuncture | 3.2% | 58,376 | 49,172 | $6.04M |
| 81001 | 3.2% | 105,409 | 91,111 | $5.93M | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 3.0% | 20,993 | 18,127 | $5.73M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.9% | 23,522 | 19,665 | $5.43M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 94,419 | 31,299 | $5.21M |
620 more codes
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.5% | 58,804 | $4.62M |
| 81025 | 2.3% | 52,303 | $4.37M | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.3% | 79,140 | $4.32M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.1% | 29,619 | $3.87M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.9% | 43,281 | $3.50M |
| A0427 | Emergency ambulance ride, advanced life support | 1.8% | 22,449 | $3.32M |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.6% | 64,378 | $3.01M |
| A0429 | Emergency ambulance ride, basic life support | 1.6% | 37,483 | $3.01M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.3% | 31,102 | $2.35M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 15,247 | $2.35M |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 1.2% | 1,674 | $2.24M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 21,389 | $1.62M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16,774 | $1.55M |
| 96401 | <1% | 1,179 | $1.54M | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 2,251 | $1.46M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 24,986 | $1.38M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,715 | $1.32M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 14,549 | $1.30M |
| A0425 | Ground mileage, per statute mile | <1% | 66,880 | $1.28M |
| 87081 | <1% | 11,946 | $1.22M | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,721 | $1.18M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 9,471 | $1.15M |
| 81003 | <1% | 12,165 | $1.14M | |
| 85018 | <1% | 20,363 | $1.05M | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 36,254 | $1.03M |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,029 | $939K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 27,560 | $927K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,797 | $925K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,123 | $885K |
| 77336 | <1% | 2,703 | $799K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 20,958 | $796K |
| 96402 | <1% | 706 | $767K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 18,110 | $764K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 28,700 | $755K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 156,162 | $742K |
| 90723 | <1% | 6,702 | $708K | |
| 87075 | <1% | 7,432 | $653K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 8,843 | $575K |
| 87070 | <1% | 3,265 | $570K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 10,931 | $556K |
| 71045 | Radiologic examination, chest; single view | <1% | 36,274 | $545K |
| 36416 | <1% | 4,826 | $512K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 17,037 | $510K |
| 73610 | <1% | 3,830 | $502K | |
| 86318 | <1% | 2,003 | $484K | |
| 93971 | <1% | 3,485 | $479K | |
| 73130 | <1% | 3,477 | $478K | |
| 99284 | Emergency room visit (serious) | <1% | 57,718 | $459K |
| 10060 | <1% | 800 | $421K | |
| 12011 | <1% | 1,283 | $412K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,519 | $404K |
| 73630 | <1% | 4,553 | $395K | |
| 72141 | <1% | 744 | $395K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,504 | $389K |
| 12001 | <1% | 1,556 | $384K | |
| 73030 | <1% | 3,751 | $382K | |
| 73562 | <1% | 4,508 | $377K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,894 | $374K |
| 73090 | <1% | 1,601 | $356K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,253 | $353K |
| 73110 | <1% | 2,564 | $344K | |
| 71250 | <1% | 1,977 | $338K | |
| 59025 | Fetal non-stress test | <1% | 14,011 | $337K |
| 85027 | <1% | 45,646 | $334K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,785 | $324K |
| 93922 | <1% | 1,827 | $313K | |
| 73140 | <1% | 1,177 | $310K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 5,937 | $305K |
| 82784 | <1% | 1,777 | $305K | |
| 97032 | <1% | 2,386 | $303K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 22,950 | $290K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 10,994 | $286K |
| 82247 | <1% | 3,559 | $282K | |
| 83655 | <1% | 4,646 | $278K | |
| 96523 | <1% | 2,512 | $276K | |
| 92526 | <1% | 7,720 | $274K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 40,656 | $265K |
| 77066 | Tomosynthesis, mammo | <1% | 2,741 | $255K |
| 84112 | <1% | 2,543 | $250K | |
| 93970 | <1% | 1,630 | $234K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 16,107 | $222K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,148 | $216K |
| 72100 | <1% | 4,449 | $215K | |
| 87150 | <1% | 4,465 | $213K | |
| A0998 | Ambulance response and treatment, no transport | <1% | 6,027 | $212K |
| 86780 | <1% | 13,002 | $210K | |
| 80061 | Lipid panel | <1% | 29,720 | $208K |
| 97113 | <1% | 6,198 | $205K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 7,989 | $198K |
| 84702 | <1% | 11,729 | $198K | |
| 87400 | <1% | 975 | $196K | |
| 93880 | <1% | 1,494 | $196K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,457 | $196K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,279 | $196K |
| 95811 | <1% | 802 | $194K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,898 | $191K |
| 76642 | <1% | 4,856 | $190K | |
| 87077 | <1% | 13,040 | $189K | |
| 74018 | <1% | 3,939 | $188K | |
| 82947 | <1% | 4,386 | $174K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,107 | $172K |
| 73080 | <1% | 1,291 | $170K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 200 | $168K |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 1,320 | $158K |
| 82728 | <1% | 9,413 | $157K | |
| 76801 | <1% | 5,983 | $156K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 30,760 | $155K |
| 73590 | <1% | 1,908 | $147K | |
| 87807 | <1% | 2,710 | $141K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 3,702 | $141K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 11,360 | $140K |
| 93925 | <1% | 1,702 | $137K | |
| 99285 | Emergency room visit (most serious) | <1% | 30,282 | $135K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,340 | $135K |
| 77300 | <1% | 414 | $134K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 16,188 | $130K |
| 92523 | <1% | 2,542 | $129K | |
| 76536 | <1% | 1,318 | $126K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 5,986 | $125K |
| 73221 | <1% | 240 | $125K | |
| 76770 | <1% | 1,547 | $122K | |
| 77065 | Tomosynthesis, mammo | <1% | 2,449 | $119K |
| 84484 | <1% | 40,630 | $116K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 27,622 | $116K |
| 73502 | <1% | 2,807 | $115K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 21,594 | $107K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,033 | $106K |
| G0378 | Hospital observation service, per hour | <1% | 23,940 | $104K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 48,554 | $104K |
| 88307 | <1% | 1,834 | $104K | |
| 87210 | <1% | 5,069 | $98K | |
| 97161 | <1% | 10,949 | $98K | |
| 84439 | <1% | 8,136 | $96K | |
| 90680 | <1% | 5,313 | $91K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 3,127 | $89K |
| 86850 | <1% | 17,158 | $89K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 1,926 | $89K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 1,710 | $86K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,278 | $83K |
| 10061 | <1% | 149 | $83K | |
| 85007 | <1% | 4,612 | $81K | |
| 95816 | <1% | 566 | $80K | |
| 88720 | <1% | 836 | $79K | |
| 12002 | <1% | 504 | $78K | |
| 85610 | <1% | 17,029 | $74K | |
| 72070 | <1% | 1,303 | $74K | |
| 82570 | <1% | 7,785 | $74K | |
| 72050 | <1% | 727 | $73K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 961 | $70K |
| 82785 | <1% | 889 | $67K | |
| 59430 | <1% | 661 | $66K | |
| 87581 | <1% | 1,282 | $64K | |
| 86803 | <1% | 13,403 | $63K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 301 | $62K |
| 71101 | <1% | 512 | $61K | |
| 82607 | <1% | 6,084 | $61K | |
| A9270 | Non-covered item or service | <1% | 5,482 | $57K |
| 70486 | <1% | 1,407 | $57K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 7,292 | $57K |
| 77080 | <1% | 309 | $54K | |
| 74021 | <1% | 1,302 | $52K | |
| 97162 | <1% | 5,792 | $52K | |
| 71271 | <1% | 315 | $48K | |
| J2704 | Injection, propofol, 10 mg | <1% | 39,668 | $48K |
| 83690 | <1% | 47,408 | $47K | |
| 73700 | <1% | 326 | $45K | |
| 73060 | <1% | 448 | $45K | |
| 97165 | <1% | 4,737 | $45K | |
| 83020 | <1% | 1,861 | $44K | |
| 87430 | <1% | 652 | $40K | |
| 97166 | <1% | 2,242 | $39K | |
| 88304 | <1% | 1,629 | $38K | |
| 86738 | <1% | 1,709 | $37K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 6,677 | $36K |
| 97016 | <1% | 344 | $36K | |
| 11982 | <1% | 122 | $35K | |
| 92610 | <1% | 1,608 | $35K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,983 | $35K |
| 87040 | <1% | 7,964 | $33K | |
| 73552 | <1% | 633 | $32K | |
| 80076 | <1% | 2,798 | $32K | |
| 93017 | <1% | 1,646 | $32K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 526 | $31K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,824 | $31K |
| 81015 | <1% | 611 | $31K | |
| 82565 | <1% | 1,048 | $31K | |
| 77412 | <1% | 2,815 | $30K | |
| 82950 | <1% | 2,984 | $30K | |
| 90707 | <1% | 1,837 | $29K | |
| 76775 | <1% | 488 | $29K | |
| 92551 | <1% | 445 | $27K | |
| 90620 | <1% | 159 | $27K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,862 | $27K |
| 76870 | <1% | 415 | $27K | |
| J3490 | Unclassified drugs | <1% | 35,726 | $26K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,274 | $26K |
| 82731 | <1% | 715 | $26K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 14,473 | $25K |
| 97035 | <1% | 459 | $25K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 511 | $24K |
| 82272 | <1% | 1,602 | $24K | |
| 87428 | <1% | 220 | $24K | |
| 82670 | <1% | 395 | $24K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,464 | $24K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 472 | $24K |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | <1% | 69 | $23K |
| 96377 | <1% | 51 | $23K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 918 | $23K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 3,233 | $23K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 1,814 | $23K |
| 36600 | <1% | 446 | $22K | |
| 82043 | <1% | 4,624 | $22K | |
| S9152 | Speech therapy, re-evaluation | <1% | 787 | $22K |
| 93270 | <1% | 83 | $22K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,420 | $22K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 27,125 | $22K |
| 77290 | <1% | 66 | $22K | |
| 90696 | <1% | 1,329 | $21K | |
| 89051 | <1% | 68 | $21K | |
| 74183 | <1% | 25 | $21K | |
| 83880 | <1% | 14,735 | $21K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,084 | $21K |
| 73070 | <1% | 101 | $21K | |
| 86762 | <1% | 7,744 | $20K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 40,606 | $20K |
| 73564 | <1% | 178 | $20K | |
| C1769 | Guide wire | <1% | 3,794 | $19K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 13,302 | $19K |
| 49083 | <1% | 32 | $19K | |
| 74230 | <1% | 206 | $19K | |
| 97116 | <1% | 7,500 | $19K | |
| 86695 | <1% | 172 | $18K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 66 | $18K |
| 87536 | <1% | 1,668 | $18K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,100 | $18K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 366 | $17K |
| 74022 | <1% | 647 | $17K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 145 | $17K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 333 | $17K |
| 85379 | <1% | 5,798 | $17K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 1,287 | $16K |
| 86308 | <1% | 376 | $16K | |
| 83540 | <1% | 8,051 | $16K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 13,296 | $15K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 11,825 | $15K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12,515 | $15K |
| 86704 | <1% | 1,197 | $15K | |
| 90651 | <1% | 1,692 | $15K | |
| 58300 | <1% | 43 | $15K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 35 | $14K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13,750 | $14K |
| 97168 | <1% | 590 | $13K | |
| 82951 | <1% | 1,492 | $13K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 7,682 | $13K |
| 85652 | <1% | 6,163 | $13K | |
| 86480 | <1% | 795 | $13K | |
| 84153 | <1% | 1,938 | $13K | |
| 76882 | <1% | 543 | $13K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 2,352 | $13K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 32,092 | $13K |
| 83735 | <1% | 30,795 | $13K | |
| 83615 | <1% | 1,359 | $12K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 13,113 | $12K |
| 97750 | <1% | 1,471 | $11K | |
| 87522 | Neg quan hep c or qual rna | <1% | 735 | $11K |
| 86580 | <1% | 1,820 | $11K | |
| 70498 | <1% | 1,016 | $11K | |
| 80164 | <1% | 2,989 | $11K | |
| 84436 | <1% | 586 | $10K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 9,472 | $10K |
| 77334 | <1% | 758 | $10K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 137 | $9K |
| 69210 | <1% | 65 | $9K | |
| 43235 | <1% | 150 | $9K | |
| 0002A | <1% | 262 | $9K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 128 | $9K |
| 0001A | <1% | 259 | $9K | |
| 86003 | <1% | 743 | $9K | |
| 73560 | <1% | 148 | $9K | |
| 82550 | <1% | 4,408 | $8K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 2,966 | $8K |
| 84146 | <1% | 786 | $8K | |
| 84132 | <1% | 1,154 | $8K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,161 | $8K |
| 95806 | <1% | 49 | $8K | |
| 87045 | <1% | 317 | $8K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 5,097 | $8K |
| 77001 | <1% | 396 | $7K | |
| 84145 | <1% | 1,431 | $7K | |
| 83001 | <1% | 694 | $7K | |
| 86706 | <1% | 1,733 | $7K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 351 | $7K |
| 51798 | <1% | 2,020 | $6K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 119 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 24,774 | $6K |
| 72040 | <1% | 67 | $6K | |
| 84703 | <1% | 245 | $6K | |
| 31645 | <1% | 55 | $6K | |
| 84403 | <1% | 1,346 | $6K | |
| 87641 | <1% | 534 | $6K | |
| 84144 | <1% | 96 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 32,604 | $6K |
| 86140 | <1% | 11,214 | $6K | |
| A4649 | Surgical supply; miscellaneous | <1% | 314 | $6K |
| 82803 | <1% | 2,963 | $6K | |
| 77280 | <1% | 15 | $5K | |
| 86900 | <1% | 20,157 | $5K | |
| 58301 | <1% | 27 | $5K | |
| 82105 | <1% | 184 | $5K | |
| 77386 | <1% | 730 | $5K | |
| 84550 | <1% | 1,223 | $5K | |
| 93458 | <1% | 137 | $5K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 226 | $5K |
| 88341 | <1% | 843 | $5K | |
| 86038 | <1% | 1,767 | $5K | |
| 84156 | <1% | 4,458 | $5K | |
| 82330 | <1% | 915 | $5K | |
| 86360 | <1% | 784 | $4K | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 83 | $4K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 89 | $4K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 1,565 | $4K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,222 | $4K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 26 | $4K |
| 83605 | <1% | 10,250 | $4K | |
| 87420 | <1% | 154 | $4K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 1,068 | $4K |
| 73660 | <1% | 27 | $4K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 21 | $4K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 825 | $4K |
| 88184 | <1% | 12 | $4K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 772 | $4K |
| 87324 | <1% | 78 | $4K | |
| 82077 | <1% | 9,682 | $3K | |
| 80050 | General health panel | <1% | 38 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 34,636 | $3K |
| 90686 | <1% | 7,639 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 16,179 | $3K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,002 | $3K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 13,899 | $3K |
| 36902 | <1% | 261 | $3K | |
| 83021 | <1% | 1,816 | $3K | |
| 31624 | <1% | 43 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,225 | $3K |
| 82378 | <1% | 345 | $3K | |
| 87140 | <1% | 5,407 | $3K | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 584 | $3K |
| 72170 | <1% | 154 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 10,667 | $3K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 5,551 | $3K |
| 84134 | <1% | 494 | $3K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,640 | $3K |
| 94668 | <1% | 19 | $2K | |
| 73100 | <1% | 19 | $2K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 494 | $2K |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 13 | $2K |
| 97164 | <1% | 235 | $2K | |
| 94760 | <1% | 409 | $2K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,456 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,159 | $2K |
| 81005 | <1% | 22 | $2K | |
| 83986 | <1% | 27 | $2K | |
| 82140 | <1% | 1,640 | $2K | |
| 86592 | <1% | 72 | $2K | |
| 52000 | <1% | 27 | $2K | |
| 70360 | <1% | 26 | $2K | |
| 92611 | <1% | 209 | $2K | |
| 73620 | <1% | 14 | $2K | |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 3,810 | $2K |
| 72072 | <1% | 25 | $2K | |
| 72052 | <1% | 12 | $2K | |
| 87640 | <1% | 139 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,250 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,971 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,595 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,395 | $2K |
| 90715 | <1% | 4,346 | $2K | |
| 70491 | <1% | 353 | $2K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 3,034 | $2K |
| 85660 | <1% | 169 | $2K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 198 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 18,043 | $2K |
| 97542 | <1% | 15 | $2K | |
| 86334 | <1% | 450 | $2K | |
| 85730 | <1% | 12,045 | $2K | |
| 88309 | <1% | 49 | $2K | |
| 86769 | <1% | 153 | $1K | |
| C1766 | Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away | <1% | 776 | $1K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 896 | $1K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 34 | $1K |
| 85460 | <1% | 158 | $1K | |
| 71100 | <1% | 14 | $1K | |
| 86705 | <1% | 63 | $1K | |
| 86870 | <1% | 157 | $1K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,099 | $1K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 4,504 | $1K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,516 | $1K |
| 84030 | <1% | 15 | $1K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 37 | $1K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 3,400 | $1K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 48 | $1K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 116 | $1K |
| 86923 | <1% | 1,040 | $1K | |
| 87255 | <1% | 28 | $1K | |
| 77049 | <1% | 12 | $1K | |
| 87505 | <1% | 14 | $1K | |
| 83516 | <1% | 668 | $1K | |
| 0352U | <1% | 103 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 982 | $986.81 |
| 80306 | <1% | 183 | $983.53 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 8,389 | $978.29 |
| 70496 | <1% | 1,047 | $971.79 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 55 | $968.36 |
| 20610 | <1% | 29 | $948.54 | |
| C9463 | Injection, aprepitant, 1 mg | <1% | 54 | $916.34 |
| 78306 | <1% | 28 | $910.26 | |
| 87449 | <1% | 567 | $888.72 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,536 | $884.66 |
| 85396 | <1% | 813 | $873.41 | |
| 74220 | <1% | 12 | $841.31 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,848 | $832.39 |
| 82746 | <1% | 2,443 | $817.65 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 2,267 | $817.00 |
| 19083 | <1% | 71 | $816.08 | |
| 80143 | <1% | 977 | $811.61 | |
| 87340 | <1% | 11,264 | $795.67 | |
| 86361 | <1% | 316 | $760.67 | |
| 87338 | <1% | 43 | $745.66 | |
| 51702 | <1% | 55 | $692.75 | |
| 87493 | <1% | 136 | $653.29 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 783 | $651.12 |
| 84100 | <1% | 5,740 | $643.56 | |
| 87186 | <1% | 14,195 | $624.17 | |
| 86304 | <1% | 13 | $621.57 | |
| 90670 | <1% | 9,055 | $601.00 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 620 | $596.33 |
| 90677 | <1% | 62 | $582.66 | |
| 88112 | <1% | 13 | $526.00 | |
| 82553 | <1% | 728 | $503.95 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 536 | $490.98 |
| 90461 | <1% | 13,173 | $459.89 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 3,855 | $452.00 |
| 94660 | <1% | 252 | $447.78 | |
| 84481 | <1% | 811 | $426.26 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,799 | $416.50 |
| 84466 | <1% | 6,259 | $415.20 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 1,916 | $408.50 |
| 86787 | <1% | 128 | $391.10 | |
| 83525 | <1% | 69 | $381.46 | |
| 86200 | <1% | 232 | $368.44 | |
| 88342 | <1% | 2,510 | $365.46 | |
| 99205 | Prolong outpt/office vis | <1% | 14 | $344.12 |
| 82533 | <1% | 55 | $322.27 | |
| 86664 | <1% | 12 | $305.94 | |
| 85045 | <1% | 2,230 | $273.05 | |
| 80178 | <1% | 83 | $264.85 | |
| 99459 | <1% | 117 | $255.05 | |
| 82150 | <1% | 161 | $237.73 | |
| 84402 | <1% | 79 | $232.60 | |
| 82010 | <1% | 114 | $232.11 | |
| 86677 | <1% | 16 | $232.09 | |
| 97163 | <1% | 141 | $228.50 | |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | <1% | 66 | $214.06 |
| 88360 | <1% | 14 | $213.12 | |
| 82952 | <1% | 1,504 | $195.75 | |
| 96376 | <1% | 3,121 | $188.31 | |
| 90647 | <1% | 6,580 | $179.66 | |
| 90662 | <1% | 169 | $179.46 | |
| 83970 | <1% | 305 | $173.63 | |
| C1729 | Catheter, drainage | <1% | 28 | $172.06 |
| 84165 | <1% | 635 | $170.16 | |
| 90633 | <1% | 3,480 | $161.10 | |
| 90656 | <1% | 106 | $157.62 | |
| 82248 | <1% | 306 | $145.52 | |
| 86901 | <1% | 20,155 | $142.23 | |
| 87101 | <1% | 12 | $132.05 | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 31 | $123.51 |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 3,580 | $118.95 |
| 84460 | <1% | 61 | $109.21 | |
| 96415 | <1% | 3,438 | $95.22 | |
| 85384 | <1% | 189 | $85.51 | |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 75 | $82.51 |
| 83520 | <1% | 39 | $81.88 | |
| 96417 | <1% | 2,838 | $78.46 | |
| 88302 | <1% | 145 | $73.03 | |
| 96367 | <1% | 3,242 | $60.64 | |
| 83883 | <1% | 419 | $51.29 | |
| 80051 | <1% | 21 | $47.01 | |
| 86431 | <1% | 907 | $45.64 | |
| 83921 | <1% | 17 | $44.56 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 930 | $41.60 |
| 96411 | <1% | 360 | $35.92 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 1,467 | $35.30 |
| 80177 | <1% | 29 | $30.25 | |
| 96416 | <1% | 550 | $28.33 | |
| 87205 | <1% | 4,135 | $24.07 | |
| 82652 | <1% | 25 | $21.04 | |
| 88300 | <1% | 25 | $18.57 | |
| 86376 | <1% | 56 | $18.49 | |
| 80179 | <1% | 840 | $14.91 | |
| 80185 | <1% | 13 | $13.69 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,821 | $12.71 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 549 | $12.66 |
| 87206 | <1% | 43 | $7.62 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 112 | $3.19 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 884 | $1.31 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 296 | $1.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,624 | $0.77 |
| 96368 | 0% | 1,190 | $0.00 | |
| 83550 | 0% | 1,176 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 1,148 | $0.00 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 63 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 234 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 373 | $0.00 |
| 90694 | 0% | 85 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 13 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 537 | $0.00 |
| 87181 | 0% | 17 | $0.00 | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 0% | 673 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 2,418 | $0.00 |
| 36430 | 0% | 1,232 | $0.00 | |
| 90716 | 0% | 1,933 | $0.00 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 130 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 150 | $0.00 |
| 87046 | 0% | 176 | $0.00 | |
| 87088 | 0% | 52 | $0.00 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 179 | $0.00 |
| 83002 | 0% | 170 | $0.00 | |
| 75574 | 0% | 25 | $0.00 | |
| J2997 | Injection, alteplase recombinant, 1 mg | 0% | 54 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 342 | $0.00 |
| 86225 | 0% | 28 | $0.00 | |
| G0379 | Direct admission of patient for hospital observation care | 0% | 145 | $0.00 |
| 86880 | 0% | 233 | $0.00 | |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 27 | $0.00 |
| 86258 | 0% | 14 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 181 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 16 | $0.00 |
| A9561 | Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries | 0% | 24 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 94 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 36 | $0.00 |
| 36561 | 0% | 12 | $0.00 | |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | 0% | 14 | $0.00 |
| 74174 | 0% | 37 | $0.00 | |
| 80320 | 0% | 504 | $0.00 | |
| J9299 | Injection, nivolumab, 1 mg | 0% | 21 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 63 | $0.00 |
| 86364 | 0% | 14 | $0.00 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 246 | $0.00 |
| 86255 | 0% | 83 | $0.00 | |
| 86300 | 0% | 90 | $0.00 | |
| A0433 | Advanced life support, level 2 (als 2) | 0% | 29 | $0.00 |
| 84480 | 0% | 18 | $0.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 45 | $0.00 |
| 96380 | 0% | 53 | $0.00 | |
| J8501 | Aprepitant, oral, 5 mg | 0% | 26 | $0.00 |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 0% | 16 | $0.00 |
| 88185 | 0% | 12 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 17 | $0.00 |
| 90688 | 0% | 27 | $0.00 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | 0% | 71 | $0.00 |
| J9022 | Injection, atezolizumab, 10 mg | 0% | 17 | $0.00 |
| 99406 | 0% | 13 | $0.00 | |
| 86800 | 0% | 12 | $0.00 | |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 35 | $0.00 |
| 85576 | 0% | 15 | $0.00 | |
| 80329 | 0% | 12 | $0.00 | |
| 84479 | 0% | 24 | $0.00 | |
| C1892 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away | 0% | 17 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 26 | $0.00 |
| 90700 | 0% | 1,681 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 1,171 | $0.00 |
| 87899 | 0% | 320 | $0.00 | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 0% | 36 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 100 | $0.00 |
| 86696 | 0% | 145 | $0.00 | |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 231 | $0.00 |
| 90734 | 0% | 1,483 | $0.00 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 303 | $0.00 |
| 88313 | 0% | 58 | $0.00 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 134 | $0.00 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 0% | 338 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 446 | $0.00 |
| 58571 | 0% | 37 | $0.00 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 701 | $0.00 |
| 29125 | 0% | 42 | $0.00 | |
| 90710 | 0% | 1,364 | $0.00 | |
| C1757 | Catheter, thrombectomy/embolectomy | 0% | 358 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 759 | $0.00 |
| 96381 | 0% | 15 | $0.00 | |
| 58661 | 0% | 182 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 81 | $0.00 |
| J9271 | Injection, pembrolizumab, 1 mg | 0% | 381 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 163 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 100 | $0.00 |
| 74178 | 0% | 40 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 311 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 269 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 137 | $0.00 |
| 87427 | 0% | 176 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 155 | $0.00 |
| 51701 | 0% | 13 | $0.00 | |
| 90685 | 0% | 27 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 126 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 19 | $0.00 |
| 82705 | 0% | 12 | $0.00 | |
| 47562 | 0% | 89 | $0.00 | |
| 90672 | 0% | 45 | $0.00 | |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 110 | $0.00 |
| 83721 | 0% | 12 | $0.00 | |
| J9263 | Injection, oxaliplatin, 0.5 mg | 0% | 34 | $0.00 |
| 84425 | 0% | 29 | $0.00 | |
| 86235 | 0% | 55 | $0.00 | |
| 90678 | 0% | 17 | $0.00 | |
| 84450 | 0% | 15 | $0.00 | |
| D2930 | Prefabricated stainless steel crown - primary tooth | 0% | 15 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 15 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 13 | $0.00 |
| 86665 | 0% | 12 | $0.00 | |
| C1788 | Port, indwelling (implantable) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMEINKE, KENNETH (CFO)
Parent organizationSPARTANBURG REGIONAL HEALTH SERVICES DISTRICT, INC
| Provider | Location | Paid |
|---|---|---|
| Pelham Medical Center | Greer, SC | $13.82M |
| Spartanburg Medical Center | Spartanburg, SC | $11.52M |
| Spartanburg Medical Center | Drayton, SC | $8.86M |
| Spartanburg Medical Center | Spartanburg, SC | $4.17M |
| Spartanburg Medical Center | Spartanburg, SC | $3.72M |
| Spartanburg Medical Center | Spartanburg, SC | $1.94M |
| Spartanburg Medical Center | Boiling Springs, SC | $1.92M |
| Spartanburg Medical Center | Spartanburg, SC | $1.39M |
| Spartanburg Medical Center | Spartanburg, SC | $990K |
| Spartanburg Medical Center | Greenville, SC | $943K |
| Spartanburg Medical Center | Spartanburg, SC | $911K |
| Spartanburg Medical Center | Gaffney, SC | $785K |
| Spartanburg Medical Center | Spartanburg, SC | $726K |
| Spartanburg Medical Center | Spartanburg, SC | $680K |
| Spartanburg Medical Center | Inman, SC | $669K |
| Spartanburg Medical Center | Pacolet, SC | $462K |
| Spartanburg Medical Center | Landrum, SC | $446K |
| Spartanburg Medical Center | Spartanburg, SC | $413K |
| Spartanburg Medical Center | Spartanburg, SC | $325K |
| Spartanburg Medical Center | Duncan, SC | $281K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.